| Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. | |
| | |
MedLine Citation:
|
PMID: 20512996 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONCLUSION: Activation of isolated KCs produced Cys-LTs. Infusion of Cys-LTs increased portal pressure and, vice versa, treatment with montelukast reduced portal pressure in rat liver cirrhosis. Therefore, montelukast may be of therapeutic benefit for patients with portal hypertension. |
| | |
Authors:
|
Christian J Steib; Manfred Bilzer; Mark op den Winkel; Susanne Pfeiler; Anna C Hartmann; Martin Hennenberg; Burkhard Göke; Alexander L Gerbes |
Related Documents
:
|
1354676 - Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker wi... 16274836 - Histological-hemodynamic correlation in cirrhosis-a histological classification of the ... 11875586 - Comparative effects of nitroglycerin on intestinal vascular capacitance and conductance. 3943776 - Isosorbide dinitrate in experimental portal hypertension: a study of factors that modul... 9502566 - Nicardipine for hypertensive emergencies in children with renal disease. 10347266 - The hemodynamics of steal syndrome and its treatment. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Hepatology (Baltimore, Md.) Volume: 51 ISSN: 1527-3350 ISO Abbreviation: Hepatology Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-31 Completed Date: 2010-06-17 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 8302946 Medline TA: Hepatology Country: United States |
Other Details:
|
Languages: eng Pagination: 2086-96 Citation Subset: IM |
Affiliation:
|
Department of Medicine II (Gastroenterology and Hepatology), Liver Center Munich, University of Munich, Grosshadern, Munich, Germany. christian.steib@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetates
/
therapeutic use* Animals Hypertension, Portal / drug therapy*, etiology, metabolism Kupffer Cells / metabolism Leukotriene Antagonists / therapeutic use* Leukotrienes / metabolism* Ligation Liver / pathology Liver Cirrhosis / complications*, pathology Male Quinolines / therapeutic use* Rats Rats, Sprague-Dawley Thioacetamide Thromboxane A2 / metabolism rho-Associated Kinases / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Acetates; 0/Leukotriene Antagonists; 0/Leukotrienes; 0/Quinolines; 57576-52-0/Thromboxane A2; 62-55-5/Thioacetamide; EC 2.7.11.1/rho-Associated Kinases; MHM278SD3E/montelukast |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
Next Document: Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibr...